Literature DB >> 23466943

Aortic root dilatation in essential hypertension: prevalence according to new reference values.

Alberto Milan1, Eleonora Avenatti, Francesco Tosello, Andrea Iannaccone, Dario Leone, Corrado Magnino, Franco Veglio.   

Abstract

BACKGROUND: Aortic root dilatation (ARD) and arterial hypertension represent two important risk factors for aortic dissection: prevalence of observed ARD is increasing - up to 12% in the latest available reports. A recently published work tested on a good number of healthy individuals new reference ranges for aortic root dimensions, suggesting new reference values with corrections for age, gender, height (pHeight) or body surface area (pBSA). AIM: The aim of the study was to evaluate the prevalence of ARD in hypertensive patients using various criteria.
METHODS: A total of 1076 untreated and treated essential hypertensive patients (mean age, 52.5 ± 2 years) were considered for this analysis. We measured proximal aortic diameters using ultrasound imaging (echocardiography). ARD was defined in three ways. First, when the observed aortic diameter was larger than that predicted for age, sex, and BSA (pBSA), second when larger than predicted by height (pHeight), and third when the aortic diameter to BSA ratio (ASi) was at least 2.1 cm/m.
RESULTS: A total of 237 patients (22% of the study population) showed at least one among the three different criteria defining aortic dilatation. Prevalence of ARD, considering singularly each one of the criteria, varied between 12.8% (pBSA) and 16.9% (pHeight).
CONCLUSION: Our study demonstrated a prevalence of ARD higher than previously reported. Our data suggest, therefore, the necessity of a correct choice of the diagnostic criterion that has to be applied in the single patient for definition of ARD. In particular, using the criterion pHeight in obese patients, we may avoid underdiagnosis of this condition.

Entities:  

Mesh:

Year:  2013        PMID: 23466943     DOI: 10.1097/HJH.0b013e32835f8fda

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  7 in total

1.  Echocardiography in hypertension: a call for standardization from the Working Group on Heart and Hypertension of the Italian Society of Hypertension.

Authors:  Cesare Cuspidi; Maria Lorenza Muiesan; Nicola De Luca; Massimo Salvetti; Enrico Agabiti-Rosei; Giuseppe Schillaci
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-11-08

2.  Etiology of bicuspid aortic valve disease: Focus on hemodynamics.

Authors:  Samantha K Atkins; Philippe Sucosky
Journal:  World J Cardiol       Date:  2014-12-26

3.  Association of aortic root dilatation with left ventricular function in patients with postoperative ventricular septal defect.

Authors:  Noritoshi Fukushima; Keiko Fukushima; Hiroki Sato; Chihiro Saito; Keiko Uchida; Jinko Yokota; Kyomi Ashihara; Nobuhisa Hagiwara
Journal:  Heart Vessels       Date:  2019-03-11       Impact factor: 2.037

Review 4.  Sex, gender, and subclinical hypertensiveorgan damage-heart.

Authors:  Cesare Cuspidi; Elisa Gherbesi; Carla Sala; Marijana Tadic
Journal:  J Hum Hypertens       Date:  2022-08-27       Impact factor: 2.877

Review 5.  Echocardiography in Arterial Hypertension.

Authors:  Giovanni de Simone; Costantino Mancusi; Roberta Esposito; Nicola De Luca; Maurizio Galderisi
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-05-02

6.  Comparison of echocardiographic changes in children with primary hypertension and hypertension due to mild to moderate chronic kidney disease.

Authors:  Gabriel Paris; Sudheer R Gorla; Aura J Arenas-Morales; Wacharee Seeherunvong; Sethuraman Swaminathan
Journal:  Pediatr Nephrol       Date:  2018-10-01       Impact factor: 3.714

7.  Aortic Root Diameter and Arterial Stiffness: Conjoint Relations to the Incidence of Cardiovascular Disease in the Framingham Heart Study.

Authors:  Ramachandran S Vasan; Rebecca J Song; Vanessa Xanthakis; Gary F Mitchell
Journal:  Hypertension       Date:  2021-10-04       Impact factor: 10.190

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.